Yesterday, Medlab revealed it had made progress expanding cannabis-based medicines into Europe.
’s () director of commercial operations Paul Vilner has outlined its business development objectives at its open day held at the Sydney suburb of Alexandria.
It plans to commercialise each of its four strategic pillars.
READ: Medlab Clinical expanding cannabis-based medicines into Europe
Medlab has 30 nutraceutical products (pharmaceutical-grade and standardised nutrients) globally, with another 10 in development.
Most of these products are sold as a companion to a prescription product and are available in over 600 pharmacies across Australia.
Pharmaceutical product range
Medlab has two cannabis-based medicines, NanaBis™ and NanaBidial™, which contain formulations of tetrahydrocannabinol (THC) and cannabidiol (CBD).
NanaBis™ has a 1:1 ratio of CBD:THC and NanaBidial™ has a 18:2 ratio of CBD:THC.
NanaBis™ and NanaBidial™ available to Australian patients for compassionate use under the government Special Access Scheme (SAS).
Spreading awareness of ability to access
Medlab has a dedicated team of medical specialist liaisons to support healthcare practitioners with patient initiation, SAS-B applications and clinical trial recruitment.
The company is actively collaborating with national clinical groups (RACGP) and patient support organisations (Chronic Pain Australia).
To date, doctors and pharmacists are reporting encouraging results, in both efficacy and medication substitution.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Medlab Clinical Ltd named herein, including the promotion by the Company of Medlab Clinical Ltd in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE